文献速递胸部肿瘤头颈与中枢神经肿瘤

拉泽替尼用于一代或二代EGFR酪氨酸激酶抑制剂治疗后中枢神经系统进展的EGFR突变非小细胞肺癌:非随机对照试验

Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项在韩国开展的多中心单臂2期非随机对照试验纳入40例一代或二代EGFR-TKI治疗后出现无症状或轻症状脑转移的EGFR突变NSCLC患者,接受拉泽替尼240 mg每日一次。可评估人群颅内客观缓解率为55%(21/38;95%CI 38.3-71.4),中位颅内无进展生存期15.8个月(95%CI 15.2-未达到),脑脊液渗透率为46.2%(95%CI 10.0-49.6),多数不良事件为1级或2级。

要点

  • 可评估人群颅内客观缓解率55%(21/38;95%CI 38.3-71.4),中位颅内无进展生存期15.8个月(95%CI 15.2-未达到)。
  • T790M阳性者颅内客观缓解率80%(4/5;95%CI 28.4-99.5),T790M阴性者43%(9/21;95%CI 21.8-66.0)。
  • 拉泽替尼脑脊液渗透率46.2%(95%CI 10.0-49.6),多数不良事件为1级或2级。

核心结论

  • 在可评估人群中,拉泽替尼对一代或二代EGFR-TKI治疗后颅内转移进展(伴或不伴脑膜转移)的EGFR突变转移性NSCLC患者显示出显著的颅内活性,且不受T790M状态影响。
  • 作者认为,对于既往EGFR-TKI治疗后中枢神经系统转移进展的EGFR突变NSCLC患者,使用拉泽替尼替代脑部局部治疗可能是一种潜在策略。

研究设计与样本

  • 多中心单臂2期非随机对照试验,在韩国开展,纳入一代或二代EGFR-TKI治疗后出现无症状或轻症状脑转移的EGFR突变NSCLC患者,数据收集时间为2021年6月至2022年4月,数据截止日期为2022年12月15日。
  • 共纳入40例患者,其中女性25例(63%),中位(范围)年龄63(29-85)岁;38例可评估肿瘤缓解,包括12例脑膜转移患者。
  • 干预为拉泽替尼240 mg每日一次。

主要发现

  • 数据截止时,中位(范围)随访时间为13.6(2.9-17.7)个月。
  • 可评估人群颅内客观缓解率为55%(21/38;95%CI 38.3-71.4);T790M阳性者为80%(4/5;95%CI 28.4-99.5),T790M阴性者为43%(9/21;95%CI 21.8-66.0),T790M未知者为67%(8/12;95%CI 34.9-90.1)。
  • 可评估人群中位颅内无进展生存期为15.8个月(95%CI 15.2-未达到),T790M阳性亚组为15.2个月(95%CI 4.2-未达到),T790M阴性亚组为15.4个月(95%CI 7.9-未达到),T790M未知亚组为18.0个月(95%CI 3.9-未达到)。
  • 拉泽替尼脑脊液渗透率为46.2%(95%CI 10.0-49.6)。
  • 大多数不良事件为1级或2级。

临床怎么用

  • 作者认为,对于既往EGFR-TKI治疗后中枢神经系统转移进展的EGFR突变NSCLC患者,使用拉泽替尼替代脑部局部治疗可能是一种潜在策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: EGFR-variant non-small cell lung cancer (NSCLC) is associated with a high rate of central nervous system (CNS) metastases, even with treatment with first-generation or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). OBJECTIVE: To investigate CNS activity with lazertinib, a third-generation EGFR TKI. DESIGN, SETTING, AND PARTICIPANTS: This multicenter single-arm, phase 2 nonrandomized controlled trial was conducted in South Korea and included patients with EGFR-variant NSCLC who had asymptomatic or mildly symptomatic brain metastases after unsuccessful treatment with first-generation or second-generation EGFR TKIs. Data were collected from June 2021 to April 2022, with a data cutoff date of December 15, 2022. EXPOSURE: Lazertinib, 240 mg, once daily. MAIN OUTCOMES AND MEASURES: The primary end point was intracranial objective response rate (iORR) in the evaluable population according to the Response Evaluation Criteria in Solid Tumours version 1.1 assessed by the investigators. Secondary end points included intracranial progression-free survival (iPFS) and iORR in patients with T790M-negative disease and isolated CNS progression as well as overall ORR, duration of response, intracranial duration of response, disease control rate, overall survival, cerebrospinal fluid penetration of lazertinib, and safety. RESULTS: Among 40 included patients, 25 (63%) were women, and the median (range) age was 63 (29-85) years. A total of 38 patients were evaluable for tumor response, including 12 patients with leptomeningeal metastases. At data cutoff, the median (range) follow-up was 13.6 (2.9-17.7) months. The iORR for the evaluable population was 55% (21 of 38; 95% CI, 38.3-71.4); for patients with T790M-positive disease, 80% (4 of 5; 95% CI, 28.4-99.5); for patients with T790M-negative disease, 43% (9 of 21; 95% CI, 21.8-66.0); and for patients with T790M-unknown disease, 67% (8 of 12; 95% CI, 34.9-90.1). The median iPFS was 15.8 months (95% CI, 15.2-not reached) for the evaluable population, 15.2 months (95% CI, 4.2-not reached) for the T790M-positive subgroup, 15.4 months (95% CI, 7.9-not reached) for the T790M-negative subgroup, and 18.0 months (95% CI, 3.9-not reached) for the T790M-unknown subgroup. The cerebrospinal fluid penetration rate of lazertinib was 46.2% (95% CI, 10.0-49.6), providing further support for its mechanism of intracranial response. Most adverse events were grade 1 or 2. CONCLUSIONS AND RELEVANCE: In this study, lazertinib had substantial CNS activity, regardless of T790M status, against the progression of intracranial metastases with or without leptomeningeal metastases after unsuccessful treatment with first-generation or second-generation EGFR TKIs in patients with metastatic EGFR-variant NSCLC. These results suggest that using lazertinib instead of brain local treatment could be a potential strategy in patients with EGFR-variant NSCLC whose CNS metastases progressed after prior EGFR TKI treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05326425.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hong MH, Choi YJ, Ahn HK, et al. Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial. JAMA Oncol. 2024. PMID: 39145962. doi:10.1001/jamaoncol.2024.2640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。